Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:DNA-dependent_DNA_polymerase
|
| gptkbp:activities |
reverse transcriptase inhibitor
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:1995
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:3_TC
gptkb:Epivir |
| gptkbp:can_be_used_with |
gptkb:abacavir
gptkb:tenofovir gptkb:emtricitabine |
| gptkbp:category |
gptkb:C
|
| gptkbp:clinical_trial |
approximately 86%
ongoing research for HIV treatment studies for hepatitis B treatment |
| gptkbp:composed_of |
chemical synthesis process
from 2',3'-dideoxy-5-fluorocytidine from 2',3'-dideoxycytidine |
| gptkbp:contraindication |
hypersensitivity to lamivudine
|
| gptkbp:discovered_by |
gptkb:Glaxo_Smith_Kline
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
oral solution
combination tablet |
| https://www.w3.org/2000/01/rdf-schema#label |
lamivudine
|
| gptkbp:ingredients |
C8 H11 N3 O3 S
|
| gptkbp:interacts_with |
gptkb:didanosine
gptkb:stavudine gptkb:zidovudine |
| gptkbp:invention |
gptkb:2011
|
| gptkbp:is_atype_of |
J05 A F05
|
| gptkbp:is_used_for |
treatment of HIV
treatment of hepatitis B |
| gptkbp:lifespan |
5 to 7 hours
|
| gptkbp:marketed_as |
gptkb:Epivir
many countries worldwide |
| gptkbp:name |
essential medicines
|
| gptkbp:pharmacokinetics |
inhibits viral replication
rapid absorption high plasma concentration reduces viral load |
| gptkbp:price |
low-cost generic available
|
| gptkbp:provides_information_on |
recommended for HIV therapy
recommended for hepatitis B therapy |
| gptkbp:research_focus |
long-term effects
combination therapies HIV resistance |
| gptkbp:side_effect |
fatigue
headache nausea diarrhea lactic acidosis neuropathy pancreatitis hepatomegaly |
| gptkbp:type_of |
134678-17-4
|